Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety. Issue 6 (3rd June 2021)

• Record Type: Journal Article
• Authors: Nebhan, Caroline A.; Johnson, Douglas B.
• Is Part Of: Expert review of anticancer therapy. Volume 21:Issue 6(2021)
• Page Start: 583
• Page End: 590
• Publication Date: 2021-06-03
• Subjects: Pembrolizumab -- nivolumab -- melanoma -- adjuvant -- resection; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1080/14737140.2021.1882856
• Languages: English
• ISSNs: 1473-7140

Abstract

ABSTRACT: Introduction : Regional or distant metastases from melanoma may be surgically resected but remain at high-risk of recurrence. Over the last few years, several treatments have been approved to mitigate this risk. These include anti-PD-1 agents, specifically pembrolizumab and nivolumab. Areas covered : Herein, we will discuss the landscape of pembrolizumab safety and efficacy used in the adjuvant setting for high-risk, resected melanoma. We place this in context with other available adjuvant therapies, and discuss subgroup analyses. Expert opinion : Anti-PD-1 therapy with either pembrolizumab or nivolumab has become a standard of care for patients with resected stage III or IV melanoma. In our practice, we generally offer these agents (which have comparable safety and efficacy profiles) to patients with resected stage IIIb–IV melanoma regardless of BRAF mutation status.